Infections and Infectious Diseases | Phase III Developments | UNITED KINGDOM

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

AstraZeneca Tests Diabetes Drug Farxiga for COVID-19

Lead Product(s): Dapagliflozin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 27, 2020

Details:

The study will test whether its protective effects extend to COVID-19, the disease caused by the new coronavirus that can lead to heart and kidney complications.

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Viiv HIV Prevention Trial Stopped Early on Efficacy

Lead Product(s): Cabotegravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Interim analysis of the HIV Prevention Trials Network (HPTN) 083 study showed that ViiV's cabotegravir is 69% more effective at preventing HIV acquisition than daily oral PrEP with emtricitabine/tenofovir disoproxil (FTC/TDF).

Glenmark Generics Europe Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Glenmark Initiates Phase 3 Clinical Trials on Favipiravir to Check Efficacy on COVID-19 Patients

Lead Product(s): Favipiravir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 12, 2020

Details:

Glenmark is the first company in India to initiate Phase 3 clinical trials on Favipiravir for COVID-19 patients in India. Favipiravir is a generic version of Avigan® of Fujifilm Toyama Chemical.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Astrazeneca Pits Fast-Rising Farxiga Against COVID-19

Lead Product(s): Dapagliflozin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 23, 2020

Details:

Trial will assess the potential Farxiga to reduce the risk of disease progression and death due to COVID-19 in patients who also have cardiovascular, metabolic or kidney risk factors.

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

ViiV Healthcare presents positive 48-week data from phase III study

Lead Product(s): Cabotegravir,Rilpivirine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 09, 2020

Details:

Findings from the ATLAS-2M phase III study showed that the administration of injectable cabotegravir and rilpivirine every two months was as effective and safe as once-monthly administration.

Summit Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Summit Therapeutics to Receive $1.0 Million Milestone Payment

Lead Product(s): Ridinilazole

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Eurofarma Laboratorios S.A

Deal Size: $3.8 million Upfront Cash: Undisclosed

Deal Type: Collaboration February 06, 2020

Details:

The milestone payment was initiated by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection.

Summit Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work

Lead Product(s): Ridinilazole

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority

Deal Size: $72.5 million Upfront Cash: Undisclosed

Deal Type: Funding January 23, 2020

Details:

The additional funding is being provided to support a new clinical trial in adolescent patients and brings the total value of the award to up to $72.5 million.

ViiV Healthcare

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

Chemspec USA 2020

Participation Not Confirmed

Update your events

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachme...

Lead Product(s): Fostemsavir

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

This application seeks approval of fostemsavir, used in combination with other antiretrovirals, for the treatment of adults with multidrug-resistant HIV-1 infection.

Find

Find Drugs for Infections and Infectious Diseases in Phase III Clinical Development in UNITED KINGDOM

United Kingdom

Product Type

Companies

AstraZeneca PLC

AstraZeneca Tests Diabetes Drug Farxiga for COVID-19

ViiV Healthcare

Viiv HIV Prevention Trial Stopped Early on Efficacy

Glenmark Generics Europe Ltd

Glenmark Initiates Phase 3 Clinical Trials on Favipiravir to Check Efficacy on COVID-19 Patients

AstraZeneca PLC

Astrazeneca Pits Fast-Rising Farxiga Against COVID-19

ViiV Healthcare

ViiV Healthcare presents positive 48-week data from phase III study

Summit Therapeutics

Summit Therapeutics to Receive $1.0 Million Milestone Payment

Summit Therapeutics

Summit Announces BARDA Expands Ridinilazole Award by $8.8 Million to Include Additional NDA-Enabling Work

ViiV Healthcare

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachme...